DA Schaer, RP Beckmann, JA Dempsey, L Huber… - Cell reports, 2018 - cell.com
Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been
approved for the treatment of hormone receptor-positive breast cancer. In this study, we use …